The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Akero Therapeutics Inc shares valued at $1,136,400 were purchased by CATRIONA YALE on May 15 ’25. At $37.88 per share, CATRIONA YALE acquired 30,000 shares.
Also, Cheng Andrew sold 30,000 shares, netting a total of over 1,244,455 in proceeds. Following the sale of shares at $41.48 each, the insider now holds 594,324 shares.
Before that, Andrew Cheng had added 120,000 shares to its account. In a trade valued at $4,782,000, the Officer bought Akero Therapeutics Inc shares for $39.85 each.
As published in a research note from BofA Securities on January 30, 2025, Akero Therapeutics Inc [AKRO] has been rated up from a Neutral to a Buy and the price target has been revised to $63 from $35. Analysts at H.C. Wainwright resumed the stock at ‘”a Buy”‘ outlook in a report released in late January. As of November 18, 2024, Citigroup has initiated its “Buy” rating for AKRO.
Analyzing AKRO Stock Performance
During the last five days, there has been a drop of approximately -5.73%. Over the course of the year, Akero Therapeutics Inc shares have jumped approximately 43.64%. Shares of the company reached a 52-week high of $58.40 on 01/27/25 and a 52-week low of $21.34 on 01/14/25. A 50-day SMA is recorded $41.31, while a 200-day SMA reached $34.58.
Support And Resistance Levels for Akero Therapeutics Inc (AKRO)
According to the 24-hour chart, there is a support level at 38.32, which, if violated, would cause prices to drop to 36.69. In the upper region, resistance lies at 40.89. The next price resistance is at 41.83. RSI (Relative Strength Index) is 46.81 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -3.03, which suggests the price will decrease in the coming days. Percent R is at 70.84%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.
